JP2018531016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531016A5 JP2018531016A5 JP2018519323A JP2018519323A JP2018531016A5 JP 2018531016 A5 JP2018531016 A5 JP 2018531016A5 JP 2018519323 A JP2018519323 A JP 2018519323A JP 2018519323 A JP2018519323 A JP 2018519323A JP 2018531016 A5 JP2018531016 A5 JP 2018531016A5
- Authority
- JP
- Japan
- Prior art keywords
- transduced
- cell
- nucleic acid
- acid sequence
- cxcr6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical group 0.000 claims 16
- 102000009410 Chemokine receptor Human genes 0.000 claims 10
- 108050000299 Chemokine receptor Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 claims 2
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 claims 2
- 102000003812 Interleukin-15 Human genes 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021162481A JP2022008805A (ja) | 2015-10-16 | 2021-10-01 | 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15190179.0 | 2015-10-16 | ||
| EP15190179 | 2015-10-16 | ||
| PCT/EP2016/074644 WO2017064222A1 (en) | 2015-10-16 | 2016-10-14 | Cxcr6-transduced t cells for targeted tumor therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021162481A Division JP2022008805A (ja) | 2015-10-16 | 2021-10-01 | 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531016A JP2018531016A (ja) | 2018-10-25 |
| JP2018531016A6 JP2018531016A6 (ja) | 2018-12-13 |
| JP2018531016A5 true JP2018531016A5 (OSRAM) | 2019-11-28 |
| JP7018387B2 JP7018387B2 (ja) | 2022-02-10 |
Family
ID=54359823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519323A Active JP7018387B2 (ja) | 2015-10-16 | 2016-10-14 | 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞 |
| JP2021162481A Pending JP2022008805A (ja) | 2015-10-16 | 2021-10-01 | 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021162481A Pending JP2022008805A (ja) | 2015-10-16 | 2021-10-01 | 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11723922B2 (OSRAM) |
| EP (1) | EP3362569B1 (OSRAM) |
| JP (2) | JP7018387B2 (OSRAM) |
| AU (2) | AU2016336868B2 (OSRAM) |
| CA (1) | CA3001507C (OSRAM) |
| DK (1) | DK3362569T3 (OSRAM) |
| ES (1) | ES2895901T3 (OSRAM) |
| WO (1) | WO2017064222A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018152572A1 (en) * | 2017-02-21 | 2018-08-30 | The University Of Adelaide | T cells expressing chemokine receptors for treating cancer |
| KR102009040B1 (ko) | 2017-04-05 | 2019-08-08 | 한국생명공학연구원 | Nk 세포 활성화 융합 단백질, nk 세포 및 이들을 포함하는 약제학적 조성물 |
| WO2019113132A1 (en) * | 2017-12-05 | 2019-06-13 | Caribou Biosciences, Inc. | Modified lymphocytes |
| US20210130438A1 (en) * | 2019-10-28 | 2021-05-06 | The Broad Institute, Inc. | Pan-cancer t cell exhaustion genes |
| CN115975943A (zh) * | 2020-07-14 | 2023-04-18 | 广州泛恩生物科技有限公司 | 基于acp5阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 |
| CN113736740A (zh) * | 2021-07-27 | 2021-12-03 | 天津市肿瘤医院（天津医科大学肿瘤医院） | 胰腺癌稳转细胞系及其构建方法和应用 |
| WO2023158997A2 (en) * | 2022-02-15 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Compositions including killer innate-like t cells and uses therof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696244B2 (en) * | 1997-07-17 | 2004-02-24 | New York University | G-coupled receptors associated with retroviral entry into cells, and therapeutic uses thereof |
| DE19822115B4 (de) | 1998-05-08 | 2004-04-08 | Heinrich-Pette-Institut | Retrovirale Gentransfervektoren |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| RU2644243C2 (ru) | 2011-10-20 | 2018-02-08 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы к cd22 |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| KR102086874B1 (ko) | 2012-04-11 | 2020-03-10 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2015028444A1 (en) * | 2013-08-26 | 2015-03-05 | Universität Zu Köln | Anti cd30 chimeric antigen receptor and its use |
-
2016
- 2016-10-14 CA CA3001507A patent/CA3001507C/en active Active
- 2016-10-14 EP EP16793764.8A patent/EP3362569B1/en active Active
- 2016-10-14 JP JP2018519323A patent/JP7018387B2/ja active Active
- 2016-10-14 AU AU2016336868A patent/AU2016336868B2/en active Active
- 2016-10-14 ES ES16793764T patent/ES2895901T3/es active Active
- 2016-10-14 WO PCT/EP2016/074644 patent/WO2017064222A1/en not_active Ceased
- 2016-10-14 US US15/768,301 patent/US11723922B2/en active Active
- 2016-10-14 DK DK16793764.8T patent/DK3362569T3/da active
-
2021
- 2021-10-01 JP JP2021162481A patent/JP2022008805A/ja active Pending
-
2022
- 2022-07-14 AU AU2022205240A patent/AU2022205240A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531016A5 (OSRAM) | ||
| JP7755890B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Rezvani et al. | Engineering natural killer cells for cancer immunotherapy | |
| Sangiolo | Cytokine induced killer cells as promising immunotherapy for solid tumors | |
| JP2019523001A5 (OSRAM) | ||
| FI3102609T3 (fi) | Menetelmiä b-solukasvaimien ja muiden syöpien hoidossa käyttökelpoisten autologisten t-solujen ja niiden koostumusten valmistamiseksi | |
| WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
| JP2017533706A5 (OSRAM) | ||
| JP2017515506A5 (OSRAM) | ||
| IL275567B2 (en) | Nucleic acid-containing lipid nano-particle and use thereof | |
| JP2019500894A5 (OSRAM) | ||
| JP2016509840A5 (OSRAM) | ||
| RU2022103870A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
| BR112019020001A2 (pt) | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais | |
| JP2016539929A5 (OSRAM) | ||
| IL292650B1 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| JP2019511236A5 (OSRAM) | ||
| JP2017535261A5 (OSRAM) | ||
| JP2017525385A (ja) | 細胞治療物質としてのｃａｒ発現ｎｋ−９２細胞 | |
| JP2017533707A5 (OSRAM) | ||
| JPWO2021021907A5 (OSRAM) | ||
| WO2023123195A1 (zh) | 一种目的基因可调控的工程化免疫细胞及其制备方法和应用 | |
| Yoon et al. | Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR) | |
| JP5751277B2 (ja) | Ｎｋ細胞活性化方法、これを用いたｎｋ細胞増殖方法及び細胞製造方法並びにｎｋ細胞を含む単核球 | |
| JP2022023136A5 (OSRAM) |